AstraZeneca's Final Data From Key Lung Cancer Study Delayed

An image of a calculator, a smartphone and a chart on a clip board
Credit: Shutterstock photo

AstraZeneca, plcAZN has announced that final overall survival data from the pivotal phase III MYSTIC study, evaluating its PD-L1 inhibitor Imfinzi in the first line lung cancer, will be presented in the second half of 2018, delayed from the first half expected previously.

The MYSTIC study evaluated Imfinzi, both as a monotherapy and in combination with tremelimumab, in treatment-naïve non-small cell lung cancer (NSCLC) patients.

AstraZeneca's shares have inched up 0.2% so far this year, comparing unfavorably with the industry 's growth of 1.7%.

This is the second negative update from AstraZeneca in relation to the MYSTIC trial. Last July, the pharma company had reported about the study's failure to meet its primary endpoint of progression-free-survival, sending the company's shares tumbling.

The study showed that Imfinzi in combination with tremelimumab could not improve progression-free survival (PFS) when compared with platinum-based chemotherapy in patients, whose tumors express PD-L1 on 25% or more of their cancer cells. Imfinzi monotherapy also fell short of showing a benefit on PFS.

However, the MYSTIC study continued thereafter as planned to assess the additional primary endpoints of overall survival (OS) for both monotherapy and combination regimen. Final OS data from both primary endpoints were initially expected during the first half of 2018.

Imfinzi is a key drug in London-based AstraZeneca's immuno-oncology (IO) pipeline, currently being evaluated for multiple cancers either alone or in combination with other regimens including Incyte's INCY epacadostat. Key phase III trials in combination with tremelimumab for hepatocellular carcinoma (HCC, liver cancer), NSCLC, small cell lung cancer and head and neck squamous cell carcinoma (HNSCC) among others are under way.

Imfinzi was launched in the United States for the first indication - second-line advanced bladder cancer - in May 2017. It was approved for the second indication in the United States - early stage lung cancer (NSCLC) - in February 2018. The drug generated sales of $19 million last year.

Talking about PD-L1 inhibitors, Merck's MRK Keytruda and Bristol Myers' BMY Opdivo have been notable successful launches. While Keytruda fetched in sales of $3.8 billion in 2017, up almost 172% year over year, Opdivo recorded $1.36 billion of revenues during the period, up 4%.

AstraZeneca carries a Zacks Rank #4 (Sell).

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Astrazeneca PLC (AZN): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Merck & Company, Inc. (MRK): Free Stock Analysis Report

Incyte Corporation (INCY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More